TY - JOUR
T1 - CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes
AU - Kerekes, Daniel
AU - Visscher, Daniel W.
AU - Hoskin, Tanya L.
AU - Radisky, Derek C.
AU - Brahmbhatt, Rushin D.
AU - Pena, Alvaro
AU - Frost, Marlene H.
AU - Arshad, Muhammad
AU - Stallings-Mann, Melody
AU - Winham, Stacey J.
AU - Murphy, Linda
AU - Denison, Lori
AU - Carter, Jodi M.
AU - Knutson, Keith L.
AU - Degnim, Amy C.
N1 - Funding Information:
Acknowledgements This research was supported by grants from Susan G. Komen for the Cure® and by the University of Notre Dame. Samples from the Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center were used in this study. We thank contributors, including Indiana University, who collected samples used in this study, as well as donors and their families, whose help and participation made this work possible. Sincere thanks also to Alexander Pearlman for assistance with manuscript preparation.
Funding Information:
This research was supported by grants from Susan G. Komen for the Cure? and by the University of Notre Dame. Samples from the Susan G. Komen for the Cure? Tissue Bank at the IU Simon Cancer Center were used in this study. We thank contributors, including Indiana University, who collected samples used in this study, as well as donors and their families, whose help and participation made this work possible. Sincere thanks also to Alexander Pearlman for assistance with manuscript preparation.
Publisher Copyright:
© The Author(s) 2017. This article is an open access publication.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Purpose While the role of natural killer (NK) cells in breast cancer therapy has been investigated, little information is known about NK cell function and presence in nonmalignant and premalignant breast tissue. Here, we investigate and quantify NK cell marker CD56 and activating ligand MICA in breast tissue with benign breast disease. Methods Serial tissue sections from 88 subjects, 44 with benign breast disease (BBD) who remained cancer-free, and 44 with BBD who later developed cancer, were stained with H&E, anti-MICA, and anti-CD56. Up to ten representative lobules were identified on each section. Using digital image analysis, MICA and CD56 densities were determined for each lobule, reported as percent of pixels in the lobule that registered as stained by each antibody. Analyses were performed on a per-subject and per-lobule basis. Results Per-subject multivariate analyses showed associations of CD56 and MICA with age: CD56 was increased in older subjects (p = 0.03), while MICA was increased in younger subjects (p = 0.005). Per-lobule analyses showed that CD56 and MICA levels were both decreased in lobules with fibrocystic change, with median levels of CD56 and MICA staining, respectively, at 0.31 and 7.0% in fibrocystic lobules compared to 0.76 and 12.2% in lobules without fibrocystic change (p < 0.001 for each). Among fibrocystic lobules, proliferative/atypical lobules showed significantly lower expression compared to nonproliferative lobules for MICA (p = 0.02) but not for CD56 (p = 0.80). Conclusion Levels of CD56+ NK cells and activating ligand MICA were decreased in breast lobules with fibrocystic change, and MICA levels showed a significant step-wise decrease with increasing histopathologic abnormality. MICA levels were also significantly decreased in older subjects, who generally have higher risk of developing cancer. These findings advance a model in which MICA promotes cytotoxic activity in CD56+ NK cells to protect against tumorigenesis in breast lobules, and suggest further research is warranted.
AB - Purpose While the role of natural killer (NK) cells in breast cancer therapy has been investigated, little information is known about NK cell function and presence in nonmalignant and premalignant breast tissue. Here, we investigate and quantify NK cell marker CD56 and activating ligand MICA in breast tissue with benign breast disease. Methods Serial tissue sections from 88 subjects, 44 with benign breast disease (BBD) who remained cancer-free, and 44 with BBD who later developed cancer, were stained with H&E, anti-MICA, and anti-CD56. Up to ten representative lobules were identified on each section. Using digital image analysis, MICA and CD56 densities were determined for each lobule, reported as percent of pixels in the lobule that registered as stained by each antibody. Analyses were performed on a per-subject and per-lobule basis. Results Per-subject multivariate analyses showed associations of CD56 and MICA with age: CD56 was increased in older subjects (p = 0.03), while MICA was increased in younger subjects (p = 0.005). Per-lobule analyses showed that CD56 and MICA levels were both decreased in lobules with fibrocystic change, with median levels of CD56 and MICA staining, respectively, at 0.31 and 7.0% in fibrocystic lobules compared to 0.76 and 12.2% in lobules without fibrocystic change (p < 0.001 for each). Among fibrocystic lobules, proliferative/atypical lobules showed significantly lower expression compared to nonproliferative lobules for MICA (p = 0.02) but not for CD56 (p = 0.80). Conclusion Levels of CD56+ NK cells and activating ligand MICA were decreased in breast lobules with fibrocystic change, and MICA levels showed a significant step-wise decrease with increasing histopathologic abnormality. MICA levels were also significantly decreased in older subjects, who generally have higher risk of developing cancer. These findings advance a model in which MICA promotes cytotoxic activity in CD56+ NK cells to protect against tumorigenesis in breast lobules, and suggest further research is warranted.
KW - Activating ligand MICA
KW - Benign breast disease
KW - CD56
KW - Natural killer cell
UR - http://www.scopus.com/inward/record.url?scp=85032704928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032704928&partnerID=8YFLogxK
U2 - 10.1007/s10549-017-4558-0
DO - 10.1007/s10549-017-4558-0
M3 - Article
C2 - 29090365
AN - SCOPUS:85032704928
SN - 0167-6806
VL - 167
SP - 649
EP - 658
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -